A Phase 2 interventional study of BG9418 (Interferon beta-1a) and Placebo in Active Ulcerative Colitis, sponsored by Biogen. Completed at 36 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-13.
Sponsored by Biogen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Colitis, Ulcerative with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Colitis, Ulcerative · Russian Federation.
Among the 73 studies in Colitis, Ulcerative with a site in Russian Federation, this one is the 51st largest by enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2008, is one of 31 in phase 2, and was the 10th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →2 of the 73 studies in Colitis, Ulcerative with a site in Russian Federation are open now. Recruiting first, the newest first:
Biocad · Sites in Russian Federation
Ages 18–45 · Men only · Healthy volunteers
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Sites in Russian Federation
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 36 · Phase 3 33 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 284 across the 70 interventional studies, 1,731 across the 3 observational. Of the 68 that completed or were terminated, 55 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 73 have an industry lead sponsor. The 10 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Biogen has 3 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 73 studies in Colitis, Ulcerative with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this study are to determine (i) the safety and tolerability of interferon beta-1a in participants with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.
Key Inclusion Criteria:
Established diagnosis of ulcerative colitis (UC) for ≥6 months
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks
Drug: BG9418 (Interferon beta-1a)
Placebo IM injection twice weekly for 12 weeks
Drug: Placebo
Avonex IM injection, self-administered per protocol
Also known as: Avonex®
Placebo IM injection, self-administered per protocol.
Percentage of Participants With a Clinical Response
Clinical response is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, accompanied by a decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore of 1 or less. Baseline was defined as the score collected during the screening period. The Mayo Score/Disease Activity Index (DAI) measures disease activity through assessment of 4 items: stool frequency, rectal bleeding, endoscopy findings, and Physician Global Assessment (PGA). Each item of the score is assessed on a 4-point scale, 0, 1, 2, or 3, with a higher score representing greater severity. In this study, the endoscopy subscore was expanded to a 5-point scale to increase sensitivity in this important dimension of the disease (0=normal/inactive disease, 4=deep ulceration). The Total Mayo Score can therefore range from 0 to13 points.
Time frame: Baseline and Week 8
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE, can therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AE's were analyzed based on the principle of treatment emergence. An AE was regarded as treatment-emergent if it was not present prior to receiving the first injection but subsequently appeared, or if it was present prior to receiving the first injection and subsequently worsened in severity.
Time frame: Up to 16 weeks
Percentage of Participants With a Decrease on Simple Clinical Colitis Activity Index (SCCAI) of ≥3 Points at Week 8
The SCCAI measures disease activity as defined by both participants and examiners and includes the following 13 items: general well-being, abdominal pain, bowel frequency, stool consistency, bleeding, anorexia, nausea or vomiting, abdominal tenderness, extra-intestinal complications (eye, mouth, joint, skin), temperature, sigmoidoscopic assessment, nocturnal bowel movements, and urgency of defecation. Scores range from 0 to 19 points, and scores \<2.5 have been shown to correlate with Patient-Defined Remission, and a decrease of \>1.5 points from Baseline correlates with Patient-Defined Significant Improvement. Baseline is defined as the mean of the screening and visit 1 scores.
Time frame: Baseline and Week 8
| Milestone | Interferon Beta-1a | Placebo |
|---|---|---|
| Started | 62 | 61 |
| Completed | 56 | 53 |
| Not completed | 6 | 8 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Physician decision | 0 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Protocol deviation | 0 | 1 |
Clinical response is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, accompanied by a decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore of 1 or less. Baseline was defined as the score collected during the screening period. The Mayo Score/Disease Activity Index (DAI) measures disease activity through assessment of 4 items: stool frequency, rectal bleeding, endoscopy findings, and Physician Global Assessment (PGA). Each item of the score is assessed on a 4-point scale, 0, 1, 2, or 3, with a higher score representing greater severity. In this study, the endoscopy subscore was expanded to a 5-point scale to increase sensitivity in this important dimension of the disease (0=normal/inactive disease, 4=deep ulceration). The Total Mayo Score can therefore range from 0 to13 points.
| percentage of participants | Interferon Beta-1a | Placebo |
|---|---|---|
| Percentage of Participants With a Clinical Response | 53 | 44 |
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE, can therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AE's were analyzed based on the principle of treatment emergence. An AE was regarded as treatment-emergent if it was not present prior to receiving the first injection but subsequently appeared, or if it was present prior to receiving the first injection and subsequently worsened in severity.
| participants | Interferon Beta-1a | Placebo |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 52 | 35 |
The SCCAI measures disease activity as defined by both participants and examiners and includes the following 13 items: general well-being, abdominal pain, bowel frequency, stool consistency, bleeding, anorexia, nausea or vomiting, abdominal tenderness, extra-intestinal complications (eye, mouth, joint, skin), temperature, sigmoidoscopic assessment, nocturnal bowel movements, and urgency of defecation. Scores range from 0 to 19 points, and scores \<2.5 have been shown to correlate with Patient-Defined Remission, and a decrease of \>1.5 points from Baseline correlates with Patient-Defined Significant Improvement. Baseline is defined as the mean of the screening and visit 1 scores.
| percentage of participants | Interferon Beta-1a | Placebo |
|---|---|---|
| Percentage of Participants With a Decrease on Simple Clinical Colitis Activity Index (SCCAI) of ≥3 Points at Week 8 | 64 | 46 |
Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Interferon Beta-1a | — | 1/62 (1.6%) | 44/62 (71%) |
| Placebo | — | 3/61 (4.9%) | 20/61 (32.8%) |
| Event | Interferon Beta-1a | Placebo |
|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 1/62 | 2/61 |
| Tibia FractureInjury, poisoning and procedural complications | 0/62 | 1/61 |
| Event | Interferon Beta-1a | Placebo |
|---|---|---|
| Influenza Like IllnessGeneral disorders | 25/62 | 6/61 |
| HeadacheNervous system disorders | 11/62 | 3/61 |
| PyrexiaGeneral disorders | 8/62 | 2/61 |
| AnaemiaBlood and lymphatic system disorders | 1/62 | 6/61 |
| Colitis UlcerativeGastrointestinal disorders | 5/62 | 4/61 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/62 | 0/61 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/62 | 0/61 |
| HypertensionVascular disorders | 3/62 | 0/61 |
| MalaiseGeneral disorders | 3/62 | 1/61 |
| Age, Continuous(years) | Interferon Beta-1a | Placebo | Total |
|---|---|---|---|
| Mean | 41.1 (21 to 64) | 41.0 (20 to 65) | 41.0 (20 to 65) |
| Sex: Female, Male(Participants) | Interferon Beta-1a | Placebo | Total |
|---|---|---|---|
| Female | 19 | 26 | 45 |
| Male | 43 | 35 | 78 |
The record gives a start of May 2008, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a